Skip to content

    Granules India

    GRANULESGood
    Healthcare·23 Jan 2026
    Management Summary

    Granules India delivered a strong Q3 FY26, with robust revenue and EBITDA growth driven by disciplined execution and improved operating leverage, despite a temporary loss in its Peptide CDMO business. The company made significant progress on regulatory fronts, with positive updates on multiple facility inspections and continued de-risking measures. Strategic initiatives, including digitalization, R&D filings, and balance sheet strengthening, are well underway to support future growth in complex generics and CDMO.

    Highlights

    8

    • Revenue of INR 1,388 crores, up 22% YoY and 7% QoQ.

    • EBITDA of INR 308 crores, growing 34% YoY, with EBITDA margin at 22.2%.

    • Gross margin stood at 63.9%, improving 216 bps YoY but decreasing 183 bps QoQ.

    • Peptide CDMO business incurred an EBITDA loss of INR 24.8 crores in Q3 FY26, but is expected to achieve positive EBITDA in Q4 FY26.

    • R&D expenses were INR 68.9 crores, representing 5% of sales.

    • Net debt decreased slightly to INR 1,015.1 crores from INR 1,024.1 crores in Q2 FY26.

    • Cash-to-cash cycle improved to 202 days from 204 days in Q2 FY26.

    • Gagillapur facility remediation is on track, with FDA not raising concerns post-January meeting.

    What Changed2

    vs Q4 FY26

    Guidance items10 → 7 (-3)Q&A highlights7 → 3 (-4)

    Key financials

    Single quarter

    08 metrics
    1. 01Revenue₹1,388 Cr+22%YoY
    2. 02EBITDA₹308 Cr+34%YoY
    3. 03EBITDA Margin22.2%+2.0%YoY
    4. 04Gross Margin63.9%+2.2%YoY
    5. 05R&D Expenses₹68.9 Cr

    Guidance & targets

    7
    CategoryTargetPriority
    Profitability
    Peptide CDMO EBITDA
    Positive EBITDA
    		High
    Profitability
    Peptide CDMO EBITDA
    Positive EBITDA
    		High
    Operational Efficiency
    Digitalization implementation
    Completion
    		Medium
    Revenue
    US Revenue Growth
    $40-50 million annual addition
    		High
    R&D
    R&D expenses
    Similar amounts
    		High
    Product Launches
    New product launches from Genome Valley
    At least 1, if not 2 products
    		High
    Product Launches
    Complex generics launches
    3 to 4 launches
    		High

    Risks & concerns

    6
    RiskSeverity

    Gagillapur Facility Warning Letter

    While remediation is on track and FDA has not raised concerns, the final resolution and reinspection timeline remain uncertain, posing a lingering regulatory risk. — Management acknowledged

    medium

    Peptide CDMO Business Losses

    The Ascelis Peptides business incurred an EBITDA loss of INR 24.8 crores in Q3 FY26 due to maintenance and execution activities, though management expects a Q4 turnaround. — Management acknowledged

    medium

    Paracetamol Price Erosion

    While demand is increasing and inventory easing, the company noted some price erosion in paracetamol, which could impact margins for this core product. — Management acknowledged

    low

    IP Litigation for Generic Adzenys

    The tentative FDA approval for generic Adzenys is subject to ongoing IP litigation, delaying its final approval and commercial launch by at least a year. — Management acknowledged

    medium

    Areas of Evasion(2)

    • Specific timeline for Gagillapur FDA reinspection
    • Exact revenue figures for specific products like lisdexamfetamine

    Q&A highlights

    3

    “We had a meeting with the virtual meeting with the FDA early January, and they have requested us for some more documentation, which we'll be submitting shortly. The most important part is the agency has not raised any concerns regarding the adequacy or pace of corrective action.”

    This addresses a major regulatory overhang, providing a positive update on the FDA's current stance and the company's progress, though a final timeline for reinspection is not yet available.

    asked by Krisha Kansara

    2 min read6 chapters

    Detailed Narrative

    01

    Q3 FY26 Financial Performance Overview

    Granules India reported a strong Q3 FY26, with revenues reaching INR 1,388 crores, marking a 22% year-on-year and 7% quarter-on-quarter growth. EBITDA grew by 34% year-on-year to INR 308 crores, resulting in an EBITDA margin of 22.2%, an improvement of 196 basis points YoY and 75 basis points QoQ. Gross margin stood at 63.9%, benefiting from a better product mix in the finished dosage segment, despite a sequential decrease of 183 basis points.

    02

    Regulatory Updates and Compliance

    The company provided positive updates on its regulatory fronts. The Gagillapur facility's remediation plan is on track, with the FDA not raising concerns post a virtual meeting in early January, and further documentation to be submitted shortly. The GLS facility received PAS approval and EIR, and the GPI facility in the USA also received EIR, closing a prior inspection. The GCH U.S. packaging site completed a GMP inspection with zero Form 483, reinforcing the company's commitment to quality systems.

    03

    Peptide CDMO Business (Ascelis Peptides)

    The Peptide CDMO platform, Ascelis Peptides, incurred an EBITDA loss of INR 24.8 crores in Q3 FY26, up from INR 28-29 crores in previous quarters, primarily due to planned maintenance and increased execution activities. However, management expressed high confidence in achieving positive EBITDA for this segment in Q4 FY26, driven by the conversion of ongoing projects into deliveries, and aims for annual profitability in FY27.

    04

    R&D and Strategic Product Pipeline

    Granules India's R&D and regulatory pipeline progressed well, with 1 EU dossier, 8 new product registrations in ROW markets, and 4 DMFs filed. Approvals included a tentative U.S. FDA approval for generic Adzenys. The company is strategically focusing on higher complexity generics, with 3-4 launches expected within the next 1-1.5 years, contributing significantly to overall growth. The Genome Valley facility is also set to launch 1-2 existing products in the next 1-2 quarters.

    05

    Operational Efficiency and Digitalization

    The company is advancing digitalization across its network, with implementation at Gagillapur expected by mid-calendar year. This, along with increasing capacities at GLS and Gagillapur, is aimed at improving operational efficiencies, productivity, and quality compliance. Investments in system enhancements (capex and opex) are planned to strengthen reliability and resilience of operations, particularly with new API plants being totally DCS driven.

    06

    Balance Sheet and Capital Allocation

    Net debt saw a slight decrease to INR 1,015.1 crores from INR 1,024.1 crores in Q2 FY26, and the cash-to-cash cycle improved to 202 days. Working capital as a percentage of sales improved to 27% from 33% at the year's beginning. The recent preferential issue strengthened the balance sheet, with proceeds earmarked for capacity expansion, efficiency drives, and value-accretive opportunities, while maintaining focus on governance and capital discipline.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.